Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Testing tumor type dependent relations between expression of ER and PgR with Ki-67 values in a single series of 1180 invasive ductal cancer patients (CROSBI ID 218451)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Kurbel, Sven ; Dmitrović, Branko ; Marjanović, Ksenija ; Kristek, Branka Testing tumor type dependent relations between expression of ER and PgR with Ki-67 values in a single series of 1180 invasive ductal cancer patients // Periodicum biologorum, 116 (2014), 4; 417-424

Podaci o odgovornosti

Kurbel, Sven ; Dmitrović, Branko ; Marjanović, Ksenija ; Kristek, Branka

engleski

Testing tumor type dependent relations between expression of ER and PgR with Ki-67 values in a single series of 1180 invasive ductal cancer patients

Background: Model of cancer-associated epigenetic changes (Kurbel S. Tumour Biol. 2013 ; 34:2011-7) proposes that dysfunctional estrogen receptors (ER), unable to adequately express progesterone receptors (PgR), beside in the ER(+)PgR(-) breast cancers might also be present in ER(+)PgR(+) tumors showing weak PgR expression. Methods: In 1180 patients with invasive ductal cancers, ER and PgR positivity were semiquantitatively classified in four groups: "0" means no positive cells ; "1+" <10% positive cells ; "2+" 11-30% positive cells ; and "3+" 31- 100% positive cells. Tumors were divided in breast cancer types. Results: Among patients older than 54, LuminalA andB1 tumors were frequently ER3+ (p<0.01), while PgR(3+) tumors were more common among Luminal A patients younger than 55 (p=0.034), suggesting that in older Luminal A or B1 patients, high ER and low PgR expression is common. Among Luminal B2 patients, ER and PgR expression did not depend much on age or on their Ki-67 values. The model predicted share of dysfunctional ERs was 732% (for Luminal A), 11.26% (B1), 12.62% (B2 & Ki-67<=20%) and 14.73% (B2 er Ki-67>20%). The predicted values matched well with the found shares of ER(3+)PgR(1+) tumors within these three types (p>0.10). Conclusions: The results support heterogeneity among ER(+)PgR(+) tumors. Future studies of ER+PgR+ phenotype variants are required since hypothetical dysfunctional ERs in some ER(+)PgR(+) breast cancer patients might alter their endocrine treatment outcomes.

breast cancer ; receptors ; estrogen ; progesterone ; Ki-67

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

116 (4)

2014.

417-424

objavljeno

0031-5362

Povezanost rada

Grafička tehnologija

Indeksiranost